ABMC Supplies San Francisco Fire Department With OralStat(R) Saliva Drugs of Abuse Test.

KINDERHOOK, N.Y. -- American Bio Medica Corporation (NASDAQ:ABMC) today announced that the San Francisco Fire Department has selected ABMC to be their sole provider of drug testing devices and support services. This new client will be using the ABMC OralStat that detects the presence or absence of six different drugs of abuse in saliva, and they will be using the device for post-accident and random drug testing of their 1,600 firefighters.

ABMC Chief Executive Officer Stan Cipkowski stated, "We are absolutely thrilled to be working with an organization of the caliber of the San Francisco Fire Department. This is the first time such a program has been implemented in the San Francisco fire department, and we are pleased that after evaluating the products and services of many companies, they chose ABMC to be their supplier of drug testing devices."

San Francisco Fire Department Executive Officer Pete Howe commented, "We looked extensively at a number of drug testing products and decided that ABMC's OralStat was state of the art and would best serve the needs of our department."

About American Bio Medica Corporation

American Bio Medica Corporation is a biotechnology company that develops, manufactures and markets accurate, cost-effective immunoassay diagnostic test kits, including some of the world's most effective point of collection tests for drugs of abuse. The Company and its worldwide distribution network target the workplace, government, corrections, clinical and

educational markets. ABMC's Rapid Drug Screen(R), Rapid One(R), Rapid TEC(R), RDS(R) InCup(TM) and Rapid TOX(TM) products test for the presence or absence of drugs of abuse in urine, while OralStat tests for the presence or absence of drugs of abuse in oral fluids. ABMC's Rapid Reader(TM) is a compact, portable device that, when connected to any computer, interprets the results of an ABMC drug screen, and sends the results to a data management system, enabling the test administrator to easily manage their drug testing program.

This release may contain forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause actual results to differ, and such differences could be material. Such risks and uncertainties include, but are not limited to, the following: continued acceptance of the Company's products, increased levels of competition in our industry, the acceptance of new products, inherent risks associated with product development and intellectual property rights, the Company's dependence on key personnel, third party sales and suppliers. There can be no assurance that the Company will be successful in addressing such risks and uncertainties and the Company assumes no duty to update any forward-looking statements based upon actual results. Investors are strongly encouraged to review the section entitled "Risk Factors" in the Company's annual report on Form 10-KSB for the fiscal year ended December 31, 2004, and quarterly reports on Form 10-QSB on file with the Securities and Exchange Commission for a discussion of risks and uncertainties that could affect operating results and the market price of the Company's common shares